Skip to main content
. 2020 Nov 11;23(12):1653–1657. doi: 10.1089/jpm.2019.0611

Table 1.

Baseline Demographic and Clinical Characteristics

  Total cohort (N = 527), n (%) Died within one-year of transplant (N = 127), n (%)
Age, years (median, range) 65.5 (60–78.4) 65.5 (60–75.2)
Gender
 Female 213 (40) 55 (43)
 Male 314 (60) 72 (57)
Race/ethnicity
 Caucasian 484 (92) 114 (90)
 Non-Caucasian 43 (8) 13 (10)
Marital status
 Married/partnered 430 (82) 106 (83)
 Single/divorced 97 (18) 21 (17)
Diagnosis
 Myeloid 366 (69) 88 (69)
 Lymphoid 161 (31) 39 (31)
Comorbidity
 HCT-CI 0–2 240 (46) 43 (34)
 HCT-CI ≥3 287 (54) 84 (66)
KPS at transplant
 <90 247 (47) 54 (43)
 ≥90 273 (53) 72 (57)
 Missing 7 1
Disease risk index
 Low/intermediate 383 (73) 80 (63)
 High/very high 144 (27) 47 (37)
Conditioning intensity
 RIC/NMA 218 (41) 51 (40)
 Myeloablative 309 (59) 76 (60)
Donor
 Matched 402 (76) 87 (69)
 Alternative 125 (24) 40 (31)
ADL/IADL
 Normal 368 (87) 80 (78)
 Impaired 55 (13) 23 (22)
 Missing 104 24
PIM user
 No 297 (56) 60 (47)
 Yes 230 (44) 67 (53)
Depression
 No 439 (83) 106 (83)
 Yes 88 (17) 21 (17)
Prior fall
 No 431 (82) 103 (81)
 Yes 96 (18) 24 (19)
Weight loss
 No 439 (83) 99 (78)
 Yes 88 (17) 28 (22)

ADL, activities of daily living; HCT-CI, hematopoietic cell transplantation-comorbidity index; IADL, instrumental activities of daily living; KPS, Karnofsky Performance Status; PIM, potentially inappropriate medication; RIC/NMA, reduced-intensity/nonmyeloablative conditioning.